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The expression of the cytochrome P450 CYP3A5 enzymes shows a wide variation across the
general population and ethnic groups. This wide disparity implies interracial differences
in drug clearance and susceptibility to diseases such as cancer. CYP3A5 polymorphisms were
rapidly determined using polymerase chain reaction–restriction fragment length polymor-
phism analysis in 113 Taiwanese patients with hepatoma, 70 with cervical cancer, 92 with
breast cancer, 82 with oral cancer, 90 with thyroid cancer, 133 with lung cancer, and 270
healthy controls. The allelic frequencies of CYP3A5*1 were 25% in hepatoma patients, 33%
in cervical cancer patients, 31% in breast cancer patients, 22% in oral cancer patients, 23%
in thyroid cancer patients, 20% in lung cancer patients, and 27% in healthy subjects. Lung
cancer patients had a significantly lower frequency (20%) of CYP3A5*1 expression than
healthy controls (p = 0.028, odds ratio = 1.49, 95% confidence interval = 1.04–2.13), but there
was no statistically significant difference between healthy controls and other cancers. We
suggest that CYP3A5*1 may play an important role in individual predisposition to lung cancer
in Taiwan.
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The CYP3A enzymes represent most of the cytochrome
P450 (CYP) activity in the liver and lung [1,2]. In
addition to other functions, CYP3A catalyzes the oxi-
dation of xenobiotics, including carcinogens, toxins,
and drugs [3]. This specific reaction converts a
procarcinogen to its carcinogen form or deactivates
about half of drugs currently in clinical use [3–5]. Four
members of the human CYP3A subfamily, CYP3A4,
CYP3A5, CYP3A7, and CYP3A43, have been identi-
fied and their expressions are differentially regulated.
CYP3A5 is found in adult tissues and represents most
of the CYP3A activity in lung.
Two linked mutations in the promoter region of the
CYP3AP1 gene, A/G (-44) and T/G (-369), are associ-
ated with CYP3A5 expression and activity [4,6]. Kuehl
et al reported a direct concordance between the A/G
(-44) polymorphism of CYP3AP1 and the CYP3A5*1
allele in Caucasians [7]. The polymorphic CYP3AP1*1
was in positive linkage with the polymorphic
CYP3A5*1 allele, and subjects with A/G (-44) in
CYP3AP1 also carried at least one CYP3A5*1 allele.
Although CYP3A5 expression is closely correlated
with the CYP3AP1*1 genotype, the expression was
better predicted by CYP3A5 genotype [7]. This obser-
© 2003 Elsevier. All rights reserved.
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vation enables correlation of CYP3A5*1 polymorphism
with CYP3A5 expression.
Inter-individual variation in CYP3A5 activity could
influence individual predisposition to cancers caused
by environmental carcinogens or endogenous
substances, such as aflatoxin B1 for liver cancer and
estrogen for breast cancer. Numerous carcinogens and
chemicals are enzymatically activated to their ulti-
mate carcinogenic form by CYP3A5. These enzymes
can also inactivate toxic substances and some carcino-
gens by similar reactions. An individual’s risk of lung
cancer increases more than 5-fold if at least one parent
has lung cancer [8], implying a role for genetic factors
in susceptibility to this cancer. In this study, we inves-
tigated CYP3A5 polymorphisms in several cancers to
explore the relationship among them.
MATERIALS AND METHODS
Blood samples (2 mL) were collected from 270 normal
individuals, 113 hepatoma patients, 70 cervical squa-
mous cell carcinoma patients, 92 breast intraductal
carcinoma patients, 133 lung squamous cell carcinoma
patients, 82 oral squamous cell carcinoma patients,
and 90 thyroid papillary adenocarcinoma patients. All
were Taiwanese. Total genomic DNA was then iso-
lated from peripheral leukocytes as described previ-
ously [9]. This study was approved by the institutional
review boards of the Chinese Medical College Hospi-
tal and the Changhua Christian Hospital.
PCR–RFLP analysis
Polymerase chain reaction (PCR)–restriction fragment
length polymorphism (RFLP) assays were used to find
A to G mutations at nucleotide (nt) 22,893 (GeneBank
AC005020) in individual samples. A Dde I restriction
enzyme site containing nt 22,893 was created using an
oligonucleotide mismatch (underlined base) in the
upstream PCR primer. An exogenous restriction site
was created by the PCR reaction in CYP3A5*3 alleles,
with a guanine (G) at nt 22,892. There was no such site
in CYP3A5*1 alleles, where there was an adenine (A) at
nt 22,892. The sequences of the primer pair for the
C Y P 3 A 5 * 1 / C Y P 3 A 5 * 3  a l l e l e s  w e r e  5 ’ -
C T C T T T A A A G A G C T C T T T T G T C T C T C A - 3 ’
(upstream, from nt 22,866 to nt 22,892 in AC005020)
a n d  5 ’ - G T T G T A C G A C A C A C A G C A A C C - 3 ’
(downstream, from nt 23,000 to nt 23,020 in AC005020),
potentially giving a 6-base-pair (bp) Dde I enzyme site
containing nt 22,893 (AC005020).
All samples used to determine CYP3A5*3 and
CYP3A5*1 genotypes were also used to determine
CYP3A5*6 genotypes. The sequences of the primer
pair used to determine CYP3A5*6 genotype were 5’-
GATAGTTCTGAAAGTCTGTGGC-3’ (upstream, from
nt 30,371 to nt  30,392 in AC005020)  and 5’-
G A G A G A A A T A A T G G A T C T A A G A A A C C - 3 ’
(downstream, from nt 30,613 to nt 30,638 in AC005020),
abolishing the endogenous Dde I enzyme site contain-
ing nt 30,597 (AC005020) in CYP3A5*6 alleles.
Each PCR was carried out in 50 +L of reaction
mixture containing 200 ng genomic DNA, 1x Taq buffer,
0.2 mM of dNTP, 0.2 +M of each primer, and 0.4 U Taq
polymerase (Protech, Taipei, Taiwan). The following
conditions were used in each cycle: 94$C for 1 minute,
annealing temperature for 1 minute, and 72$C for 90
seconds. The annealing temperature was 58$C for
CYP3A5*3 and 60$C for CYP3A5*6 primer pairs. Primer-
directed amplification was repeated for 35 cycles.
After PCR amplification, the DNA fragments were
digested with Dde  I  at 37$C for 4 hours before
electrophoresis on a 3.5% agarose gel in 0.5x TAE
(Tris-acetate-EDTA) buffer. PCR products were dis-
tinguished by the size of the main fragments on
electrophoresis. There is an endogenous Dde I site 20
bp from the 3’ end of the amplified CYP3A5*3 product
in the CYP3A5*3/CYP3A5*1 assay, so three fragments
(20, 110, and 25 bp) are released by Dde I digestion of
the 155 bp fragment from a patient homozygous for
CYP3A5*3. In the CYP3A5*1 allele, only two fragments
(130 and 25 bp) are released because no new Dde I
recognition site is created (Figure 1, lanes 1 and 2). The
PCR-amplified product of the CYP3A5*6 reaction (168
bp) is digested into three fragments (120, 128, and 20
bp) for CYP3A5*6 alleles or four fragments (120, 103,
25, and 20 bp) for CYP3A5*1 alleles (Figure 2, lanes 1
and 2).
Sequencing analysis of amplified fragments
PCR-amplified products were purified using a PCR
purification kit (QIAquick, Qiagen Inc., Valencia, CA,
USA). PCR products containing polymorphic
CYP3A5*1/*1, CYP3A5*1/*3, or CYP3A5*3/*3 alleles
were then subjected to direct sequencing using an ABI
PRISM 310 Genetic Analyzer (Applied Biosystems,
San Francisco, CA, USA). The PCR primers were also
used for sequencing.
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Statistical analysis
The differences in distribution of CYP3A5 genotypes
between tumor patients and healthy controls were
determined by the Chi-squared test.
Probability values of less than 0.05 were regarded
as statistically significant. Odds ratios (ORs) with 95%
confidence intervals (CIs) were calculated using un-
conditional logistic regression and adjusted for age
and gender to estimate the association between cer-
tain genotypes and diseases. All statistical analyses
were performed using the Statistical Analysis System
software, version 6.12 (SAS Institute, Cary, NC, USA).
RESULTS
Polymorphisms at nt 22,893 for CYP3A5*3
The expected 110 bp fragment of the CYP3A5*3 allele
was visible on 3.5% agarose gel, whereas the 20 and 25
bp fragments were indistinguishable and less intense on
the gel (Figure 1, lanes 5 and 6). The expected 130 bp
fragment for the CYP3A5*1 allele was distinguishable
from the CYP3A5*3 110 bp fragment and the uncut 155
bp band on the gel (Figure 1). Four fragments were
expected in the PCR products of heterozygous
(CYP3A5*1/*3) subjects. However, only the longer frag-
ments (110 and 135 bp) were observed; the shorter frag-
ments (35 and two copies of 20 bp) were retarded at a
similar distance on the gels (Figure 1, lanes 3 and 4).
The CYP3A5 allelic frequencies and genotypes for
the 580 patients and 270 controls are shown in Tables
1 and 2. There was a significantly lower frequency of
CYP3A5*1 polymorphism in patients with lung cancer
(p = 0.028, OR = 1.49, 95%CI = 1.04–2.13) than in
normal controls, but there was no difference between
normal controls and other cancers.
Frequencies of CYP3A5*1 are similar among
male and female lung cancer patients
Of the lung cancer patients, 105 were male and 28 were
female, giving an incidence ratio of nearly 4 to 1.
Frequencies of the CYP3A5*1 allele were 20% and 18%
in males and females, respectively (Table 3). The smok-
ing histories of these patients were further analyzed:
there were 96 male smokers or ex-smokers, but there
were no smokers among the women. The allelic frequen-
cies of CYP3A5*1 in male smokers and non-smokers
were 22% and 5.6%, respectively, and the incidence
ratios of carrying at least one CYP3A5*1 allele were
35% and 11%, respectively. For normal controls, the
incidence ratio of carrying at least one CYP3A5*1 allele
was 48% (Table 2).
Frequencies of polymorphisms at nt 30,597
for CYP3A5*6
No CYP3A5*6 allele was identified in the tested
samples. We sequenced the PCR products from some
of the samples to accurately confirm these results.
Figure 1. Dde I digestion of the PCR products for CYP3A5*1 and
CYP3A5*3. (A) Lanes 1 and 2 are CYP3A5*1/*1; lanes 3
and 4 are CYP3A5*1/*3; lanes 5 and 6 are CYP3A5*3/*3;
lane U is the uncut control; lane M is the 100 bp ladder marker.
(B) Schematic presentation of the PCR products after Dde I
digestion.
Figure 2. Dde I digestion of the PCR products for CYP3A5*1 and
CYP3A5*6. (A) Lanes 1 and 2 are CYP3A5*1/*1; lane U
is the uncut control; lane M is the 100 bp ladder marker.
(B) Schematic presentation of the PCR products after Dde I
digestion.
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DISCUSSION
CYP3A5 polymorphisms influence CYP3A5 activity
[7]. People with at least one CYP3A5*1 allele have
relatively high levels of CYP3A5 expression in their
liver and intestines. The number of copies of polymor-
phic CYP3A5*3 and CYP3A5*6 alleles in a person di-
rectly affects CYP3A5 expression. There are consider-
able interracial and inter-individual differences in
CYP3A5 activity. The results of this study are the first
to show that no CYP3A5*6 allele was present in
Taiwanese. This finding further demonstrates that
CYP3A5*6 is rare not only in Caucasians and African
Americans but also in Taiwanese.
Among Taiwanese, the allelic frequency of
CYP3A5*1 is approximately 27%, with 48% of normal
subjects bearing at least one CYP3A5*1 allele. These
individuals are predicted to express relatively high
amounts of CYP3A5 enzymes. Consequently, they are
more likely to clear drugs that are inactivated by
CYP3A5 more efficiently and have different risks of
diseases associated with CYP3A5 expression.
CYP enzymes are the primary enzymes that catalyze
procarcinogens to carcinogens. For instance, CYP3A5
Table 1. Allelic frequencies of CYP3A5 polymorphisms in different cancers in Taiwanese patients
CYP3A5*1 CYP3A5*3 p value
Hepatocellular carcinoma 57/226 (25%) 169/226 (75%) 0.604
Cervical cancer 46/140 (33%) 94/140 (67%) 0.173
Breast cancer 57/184 (31%) 127/184 (69%) 0.304
Lung cancer 53/266 (20%) 213/266 (80%) 0.028
Oral cancer 36/164 (22%) 128/164 (78%) 0.193
Thyroid cancer 42/180 (23%) 138/180 (77%) 0.327
Normal 146/540 (27%) 394/540 (73%)
No CYP3A5*6 was found in this study.
Table 2. Genotypic frequencies of CYP3A5 polymorphisms in different cancers in Taiwanese patients
CYP3A5*1/*1 CYP3A5*1/*3 CYP3A5*3/*3
Hepatocellular carcinoma 8/113 (7%) 41/113 (36%) 64/113 (57%)
Cervical cancer 6/70 (9%) 34/70 (49%) 30/70 (43%)
Breast cancer 12/92 (13%) 33/92 (36%) 47/92 (51%)
Lung cancer 11/133 (8%) 31/133 (23%) 91/133 (68%)
Oral cancer 3/82 (4%) 30/82 (37%) 49/82 (60%)
Thyroid cancer 5/90 (6%) 32/90 (36%) 53/90 (59%)
Normal 16/270 (6%) 114/270 (42%) 140/270 (52%)
Table 3. Comparison of sex, mean age, smoking status, and frequency of CYP3A5 polymorphisms in lung cancer
patients
Sex (n) Smoking n Mean age* CYP3A5*1 CYP3A5*3
Male (105) Yes 96 62.3 42/192 (22%)† 150/192 (78%)‡
No 9 62.3 1/18 (5.6%)† 17/18 (94%)‡
Female (28) Yes 0 – – –
No 28 57.5 10/56 (18%) 46/56 (82%)
*Calculated according to age on day of admission to hospital; †total allelic frequency of CYP3A5*1 in males, 20%; ‡total allelic frequency of
CYP3A5*3 in males, 80%.
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can catalyze the estrogen, estrone (E1), to its putative
carcinogen form, 16_-hydroxy E1 (16_-OHE1) in hu-
mans [10]; the chemical carcinogen, aflatoxin B1, is
also converted to its carcinogen form (aflatoxin 8,9-
oxide) by CYP3A5 [11]. All data point to the induction
o f  t u m o r i g e n e s i s  b y  C Y P 3 A 5  e x p r e s s i o n .
Consequently, inter-individual variations in CYP3A
activity could influence individual predisposition to
cancers that are caused by environmental carcinogens,
such as those of the liver [11] and lung [12]. Our study
used the CYP3A5*1 allele as a CYP3A5 expression
marker, and the data showed that CYP3A5 expression
per se did not significantly influence the development
of liver, cervix, breast, oral, and thyroid cancers.
However, lung cancer was an exception.
The lung is the primary site of exposure for many
inhaled chemicals and carcinogens. As a result, it is
the major target for chemical-induced diseases such as
lung cancer. Lung cancer has been regarded as a
disease that is determined solely by exposure to envi-
ronmental pollutants. Cigarette smoke is the most
common source of carcinogens for lung cancer.
However, only a small proportion of cigarette smok-
ers ultimately develop lung cancer. One reason is that
many of the carcinogens derived from cigarette smoke
need to be enzymatically activated to their carcino-
genic form. For example, benzo[a]pyrene needs to be
activated to benzo[a]pyrene diol epoxide. CYP3A5 is
the most commonly expressed enzyme in the lung,
which might be expected for the enzyme implicated as
partly responsible for the inter-individual differences
in susceptibility to a multitude of lung cancers.
Surprisingly, our data did not show the expected
higher proportion of lung cancer patients (than of
normal individuals) carrying the CYP3A5*1 allele(s).
On the contrary, there was a much lower CYP3A5*1
carriage rate in lung cancer patients than in normal
individuals or other cancer patients, implying that
CYP3A5 decreased lung cancer susceptibility. Other
than activating procarcinogens, the lower CYP3A5*1
carriage rate in lung cancer patients implied that
CYP3A5 could detoxify carcinogens that cause lung
cancer, although more studies are needed to prove
this.
Patients’ smoking histories were available for fur-
ther analysis of the relationship between CYP3A5*1
and smoke-related lung cancer. Among the lung can-
cer patients, 96 were smokers or ex-smokers who
smoked more than 0.5 packs/day; all were male. A
slightly higher percentage of smokers with lung can-
cer carried CYP3A5*1/*1 or CYP3A5*1/*3 (35%, 34/96)
than of all lung cancer patients (31%), although this
was much lower than the 48% of healthy controls. It
has been reported that cigarette smoking does not
induce expression of CYP3A enzymes [2]. Our results
suggest that the CYP3A5*1 allele does not directly
contribute to the development of lung cancer in ciga-
rette smokers. This implies that conversion of smoke-
derived procarcinogens to carcinogens is more likely
to be catalyzed by other CYP enzymes that are induced
by smoking, such as CYP1A1 or CYP2D6.
Nine male and all 28 of the female lung cancer
patients were non-smokers. One was homozygous for
the CYP3A5*1 allele. Both the CYP3A5*1 genotype and
the allelic frequency in male non-smokers were lower
than those in other cohorts. There was also a lower
frequency of CYP3A5*1 among female lung cancer
patients, similar to the observation in other lung can-
cer patients including smokers. Thus, individual sus-
ceptibility to lung cancer may be partly dependent on
the CYP3A5 genotype, regardless of smoking status.
We concluded that individual differences in suscepti-
bility to lung cancer are, in part, inherited, and the
CYP3A5*1 allele may play an inhibitory role in the
development of lung cancer.
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